Recent research by Ando et al. (2021), demonstrated that EGFR activation in head and neck squamous cell carcinoma cells triggers the phosphorylation of the Hippo pathway component, MOB1, which inhibits LATS1/2 function, leading to YAP/TAZ activation. Here, EGFR is linked to head and neck squamous cell carcinoma.